• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom study shows strong accuracy for next-gen G7 CGM in pediatric T1D patients

April 29, 2022 By Sean Whooley

Dexcom G7
[Image from Dexcom]
Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.

San Diego-based Dexcom’s study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

Data from sensors, worn on the upper arm and abdomen, were available from 127 of 132 participants aged seven to 17 years old across 10.5 days of use, various glucose concentration ranges and various rates of glucose change for comparisons with temporally matched venous blood glucose measurements (YSI).

According to the published study, data was also available from 28 of 32 patients aged two to six for whom capillary (fingerstick) blood provided comparator glucose values.

Overall mean absolute relative difference (MARD) — a measure of accuracy — registered at 8.1% for arm-placed sensors, remaining in line with previous data that recorded MARD of 8.2% for adults and 8.1% MARD in pediatric patients. MARD registered at 9% for abdomen-placed sensors in the 7-17 group, while the 2-6 group provided an overall MARD of 9.3%.

Additionally, the study demonstrated that the 12-hour extended grace period for the G7 provides consistently reliable and accurate readings, while no clinically significant difference in accuracy when comparing arm-placed sensors and abdomen-placed sensors.

Dexcom CEO Kevin Sayer said on the company’s first-quarter earnings call yesterday that he expects the G7, currently available in Europe under CE mark, to still have a “meaningful” U.S. launch this year once it garners FDA approval.

Sayer noted that Dexcom’s teams are having preliminary discussions with payers to drive market access and preparing the addition of incremental G7 lines in advance of the loss to support the expected ramp in demand once the G7 wins approval. The company is also working with insulin delivery partners to ensure that connected pumps and pens are integrated with the new CGM.

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Dexcom

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS